ATR vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AptarGroup exhibits strong financial health with a Piotroski F-Score of 8/9, indicating robust fundamentals and consistent profitability. The company trades below its growth-based intrinsic value of $186.14 but at a premium to its Graham defensive value of $77.42, reflecting reasonable valuation given its earnings momentum. Despite solid ROE of 15.62% and low debt/equity of 0.46, insider selling and weak technical trend signal caution. Analysts recommend a 'buy' with a target price of $159.14, implying 26% upside, though recent price performance remains negative over the past year.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ATR vs LLY: Head-to-Head Comparison
This page compares AptarGroup, Inc. (ATR) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.